Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 138, Issue 5, Pages 1292-+Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2016.05.029
Keywords
Exercise-induced bronchoconstriction; exercise-induced bronchospasm; exercise-induced asthma; exercise-induced bronchoconstriction pathogenesis; diagnosis; differential diagnosis and therapy; nonpharmacologic; pharmacologic
Categories
Funding
- TEVA
- GlaxoSmithKline
- AstraZeneca
- Merck
- National Institutes of Health (NIH)
- Amgen
- Genentech/Novartis
- Circassia
- Meda
- Mylan
- Sanofi
- Sunovion
- Bausch Lomb
- Johnson Johnson
- Novartis
- Pearl Therapeutics
- Genentech
- Pfizer
- Allergy Therapeutics
- Alcon
- Agency for Healthcare Research Quality [1K08HS024599-01]
- American College of Allergy, Asthma, and Immunology
- Reach MD
- Thermo Fisher Scientific
- California Society for Allergy and Immunology
- Allergy and Asthma Network
- New England Society for Allergy
- UCLA/Harbor Heiner Lectureship
- Medscape
- Western Michigan School of Medicine
- Canadian Society of Allergy and Clinical Immunology
- Pennsylvania Society for Allergy and Immunology
- NIH
- Quintiles
- PRA
- UpToDate
- Annals of Allergy
- Pulmonary & Allergy Associates Atlantic Health System
- Thermo Fisher
- NIAID
- Astellas
Ask authors/readers for more resources
The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence-and consensus-based document.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available